Comprehensive biomarker testing can identify EGFR or other mutations in your lung cancer. Learn the benefits of testing and how it can help shape treatment.

Dr. Chakraborty and his team report that mutations in the Epidermal Growth Factor Receptor (EGFR) gene—which ... to support the progression of lung adenocarcinoma, the most common type of ...

EGFR inhibitors are efficacious as second ... chemotherapy in former smokers and light smokers from East Asia with lung adenocarcinoma. In this open-label, phase III study, patients were randomly ...

I never thought in a million years that this would happen to me … especially so young,” Brooklynite Jaclyn Keely told The ...

Mutations in the estrogen growth factor receptor (EGFR) gene are among the most common genetic alterations found in non-small cell lung cancer (NSCLC), occurring in 34% of all lung adenocarcinomas.

Dr. Suresh S. Ramalingam explains that patients with stage 3 lung cancer who undergo chemotherapy and radiation may develop ...

Researchers hope that identifying the genomic alterations specific to transformed small cell lung cancer (SCLC) can help ...

Afatinib has broad activity against EGFR mutations. However, the approval for uncommon mutations was based on data from 38 ...

Lung adenocarcinoma occurs when cancer forms in ... including the TP53, KRAS, and EGFR genes. A mutation (change) in the genes that control cell growth, division, or repair of damaged DNA can ...

Drug resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, occurring via secondary mutations or bypass pathways, is frequent among non-small-cell lung cancer patients.

Some non-small-cell lung cancers (NSCLC) have changes in a gene called EGFR. If your NSCLC has these mutations, your doctor likely will recommend treatment with targeted therapies that block EGFR.